Aciphin (Inj) 250mg vial i.v

Aciphin 250mg IV Injection — Ceftriaxone 250mg Intravenous Powder

1. Indications & Clinical Uses

Aciphin® is ACI Pharmaceuticals' brand of ceftriaxone sodium, a third-generation cephalosporin antibiotic with a broad spectrum of bactericidal activity, long half-life enabling once-daily dosing, and excellent tissue penetration including the cerebrospinal fluid (CSF). The 250mg IV formulation is used for lower-dose parenteral treatment or for paediatric dosing.

Indications (from ACI prescribing data):

Lower respiratory tract infections (CAP, HAP); renal and urinary tract infections (complicated and uncomplicated UTI, pyelonephritis); septicaemia (bloodstream infections); skin, soft tissue, bone and joint infections; intra-abdominal infections (peritonitis, biliary infections); bacterial meningitis; uncomplicated gonorrhoea (single IM dose 250mg); pelvic inflammatory disease (PID); ENT infections (sinusitis, otitis media, tonsillitis); acute bacterial otitis media; bacterial endocarditis (HACEK organisms: Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella); surgical prophylaxis; typhoid fever; and infections in immunocompromised, neutropenic, and cancer patients.

Diabetes relevance: Diabetic patients face dramatically higher risk of serious bacterial infections: diabetic foot infections, complicated UTIs, pneumonia, and sepsis. Ceftriaxone's broad spectrum, once-daily dosing, and dual hepatic-renal elimination make it particularly valuable for diabetic patients who often have both hepatic and renal complications. Aciphin IV is used in hospitalised diabetic patients with diabetic foot infections, febrile UTIs, and systemic infections.

2. Mechanism of Action

Ceftriaxone is bactericidal. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) — the enzyme complexes responsible for the final stages of peptidoglycan cross-linking in the bacterial cell wall. PBP binding prevents cell wall strengthening during bacterial replication, causing structural weakness, osmotic lysis, and rapid bacterial death. Ceftriaxone is active against beta-lactamase-producing organisms that are resistant to penicillins, as it has relative stability to many beta-lactamases (both penicillinases and cephalosporinases) of Gram-negative and Gram-positive bacteria. It is bactericidal against most susceptible Gram-positive and Gram-negative pathogens including S. pneumoniae, H. influenzae, E. coli, K. pneumoniae, P. mirabilis, Neisseria spp., and Salmonella typhi.

3. Dosage & Administration (Official ACI Data)

Adults and children >12 years: 1–2 g once daily (every 24 hours). In severe infections: 2–4 g/day. Single IV doses >1 g by IV infusion only.

Children (15 days – 12 years): 20–50 mg/kg once daily; up to 80 mg/kg in severe infections. Doses ≥50 mg/kg by IV infusion over ≥30 minutes.

Neonates (up to 14 days): 20–50 mg/kg/day by IV infusion over 60 minutes. Maximum 50 mg/kg/day.

Special indications:
Uncomplicated gonorrhoea: 250 mg single IM dose.
Bacterial meningitis: Initial 100 mg/kg/day (max 4 g/day) for children.
Bacterial endocarditis (HACEK): 2–4 g/day IV infusion.
Surgical prophylaxis: 1 g at induction (colorectal: 2 g).
Duration: Continue 2–3 days after signs and symptoms resolve (typically 4–14 days depending on infection).

IV Reconstitution: Dissolve 250 mg in 5 ml Water for Injection BP. Administer by slow IV push over 5 minutes. Once reconstituted: stable 6h at room temperature, 24h at 5°C.

Renal impairment: No dose adjustment for creatinine clearance >10 ml/min. If CrCl <10 ml/min: maximum 2 g/day. No haemodialysis dose supplementation needed.

Hepatic impairment: No dose reduction needed if renal function is intact.

4. Side Effects

Ceftriaxone is generally well tolerated. Side effects are relatively infrequent, usually mild, and reversible. GI: Nausea, vomiting, diarrhoea, loose stools, abdominal pain (most common — 2–4%). Clostridioides difficile-associated diarrhoea (CDAD) may occur during or after treatment. Haematological: Eosinophilia, thrombocytosis or thrombocytopenia, leucopaenia. Hepatic: Transient elevation of liver enzymes (ALT, AST, ALP), rarely jaundice. Biliary: Biliary sludge/pseudolithiasis (especially in children on high doses or prolonged therapy — ultrasound reversible on discontinuation). Renal: Nephrolithiasis (renal stones) with high-dose long-term use. CNS: Rarely: convulsions, dizziness, involuntary movements, fever. Injection site: Pain, phlebitis at IV site. Hypersensitivity: Rash, urticaria; rarely anaphylaxis (cross-reactive with penicillin in 1–2% of penicillin-allergic patients).

Critical interaction — DO NOT MIX: Ceftriaxone must NEVER be mixed with calcium-containing IV solutions (including Ringer's Lactate and Hartmann's solution) — fatal precipitate formation in lung and kidney, especially in neonates. Use separate IV lines.

5. Contraindications

Contraindicated in: hypersensitivity to ceftriaxone, any cephalosporin, or severe penicillin allergy (anaphylaxis history); premature infants and neonates with hyperbilirubinaemia; concurrent calcium-containing IV solutions in neonates (fatal precipitate); patients on IV calcium infusions requiring simultaneous IV ceftriaxone.

6. Warnings & Precautions

Anaphylaxis: Administer test dose and monitor for first 30 minutes. Ensure availability of epinephrine and resuscitation equipment. Anaphylactic shock requires immediate IV epinephrine followed by glucocorticoids.
CDAD: If diarrhoea develops during or after treatment, consider C. difficile infection. Avoid antiperistaltic agents.
Biliary pseudolithiasis: May be asymptomatic; reversible on discontinuation. Particularly in children with high doses or prolonged courses.
Neonates: Do not use in hyperbilirubinaemic neonates (ceftriaxone displaces bilirubin from serum albumin — risk of kernicterus). Do not use with calcium-containing IV fluids in neonates.
Diabetes: Diabetic patients with renal impairment (CrCl <10 ml/min) require dose adjustment. Monitor renal function and hepatic enzymes in patients on prolonged courses.

7. Drug Interactions

No impairment of renal function with concurrent frusemide or aminoglycosides (safe to co-administer per ACI official data). However: Avoid mixing in the same IV line as calcium (precipitation). Aminoglycosides + ceftriaxone: synergistic for severe infections but administer separately. Warfarin: ceftriaxone may potentiate anticoagulant effect (inhibits gut flora that produce vitamin K) — monitor INR. NSAIDs and probenecid: negligible interaction. Alcohol: no specific interaction but avoid with systemic infections generally.

8. Pharmacokinetics

Complete IV bioavailability (100%). Protein binding: 85–95% (albumin-bound — decreases with increasing concentration, relevant for dosing in hypoalbuminaemia). Volume of distribution: 6–14 L. Half-life: 6–9 hours — enables true once-daily dosing. Dual elimination: ~50% renal (unchanged), ~50% hepatic (biliary excretion of unchanged drug). Excellent penetration into: lungs, bile, bone, CSF (especially in meningitis), middle ear fluid, prostate, and peritoneal fluid. Therapeutic CSF concentrations achieved in inflamed meninges — first-line for bacterial meningitis in Bangladesh.

9. Storage & Stability

Dry powder: below 30°C, protected from light. After reconstitution with Water for Injection: stable 6 hours at room temperature (25°C) and 24 hours at 5°C. Use freshly prepared solutions. Do not freeze reconstituted solution. After mixing for IV infusion: use within 6 hours.

10. Missed Dose / Course Completion

For hospitalised patients, doses are administered by healthcare workers — missed doses should be given as soon as possible and the schedule resumed. Continue treatment for at least 2–3 days after resolution of signs and symptoms. Complete the full prescribed course to prevent treatment failure and resistance development.

11. Overdose

No specific antidote. Haemodialysis and peritoneal dialysis do not significantly remove ceftriaxone. Symptomatic and supportive treatment. Monitor neurological status (high-dose ceftriaxone can cause seizures in predisposed patients).

12. Clinical Evidence

Ceftriaxone is a WHO Essential Medicine and the most widely used parenteral antibiotic globally. Once-daily dosing confirmed clinically equivalent to twice-daily dosing for most indications (multiple RCTs). Standard of care for: community-acquired pneumonia (BTS, IDSA, BSAC guidelines), bacterial meningitis (first-line per WHO), typhoid fever (preferred in Bangladesh), gonorrhoea (WHO recommended 250mg single dose), and empirical treatment of sepsis. Dual (renal + hepatic) elimination makes ceftriaxone uniquely safe across a wide range of organ impairment — the most important practical advantage in Bangladesh's diabetic patient population where renal impairment is prevalent.

13. Patient / Caregiver Counselling

• Ceftriaxone IV requires healthcare professional administration — do not attempt self-injection.
• Report any skin rash, difficulty breathing, or swelling immediately (signs of allergic reaction).
• Complete the full course as prescribed — stopping early risks treatment failure and resistant infection.
• Diarrhoea during treatment: report to your doctor — could indicate C. difficile.
• Diabetic patients with diabetic foot or UTI: Ceftriaxone therapy usually needs to be combined with other antibiotics for polymicrobial diabetic foot infections — follow your physician's full regimen.
• This IV formulation is for IV administration only — the accompanying solvent is Water for Injection BP, not lidocaine (which is for the IM formulation).

Frequently Asked Questions (FAQ)

Q1. What is the difference between Aciphin IV and Aciphin IM?
Aciphin IV (intravenous) is reconstituted with Water for Injection BP and administered directly into a vein over 5 minutes. Aciphin IM (intramuscular) is reconstituted with lidocaine hydrochloride 1% solution (Xylone® 1%) to reduce injection pain and administered deep into a muscle (gluteal). The drug content (ceftriaxone) is identical. The key rule: NEVER administer an IM-prepared lidocaine solution intravenously — this causes serious cardiac toxicity from the lidocaine. The two preparations must not be confused or interchanged. Each Aciphin IV box includes Water for Injection; each IM box includes Xylone 1% (lidocaine solution).

Q2. Is ceftriaxone safe for diabetic patients with kidney disease?
Ceftriaxone has a uniquely safe profile in renal impairment compared to other antibiotics. Unlike aminoglycosides (nephrotoxic) or vancomycin (requires dose adjustment), ceftriaxone requires dose adjustment only for very severe renal failure (CrCl <10 ml/min, maximum 2g/day). For most diabetic patients with mild-moderate nephropathy (CrCl >10 ml/min), standard ceftriaxone doses require no adjustment. This dual hepatic-renal elimination is one of the main reasons ceftriaxone is the preferred parenteral antibiotic for diabetic patients with infection.

Q3. How long should a ceftriaxone course last?
Duration depends on the infection: uncomplicated UTI/LRTI: 5–7 days; complicated UTI/pyelonephritis: 10–14 days; pneumonia: 7–10 days; typhoid: 7–14 days; septicaemia: 10–14 days or longer; meningitis: 10–14 days; gonorrhoea: single dose (250mg IM). The general rule from ACI prescribing information: continue at least 2–3 days after complete resolution of signs and symptoms. For diabetic foot infections, specialist guidance is essential as courses may extend to 4–6 weeks for osteomyelitis.

Q4. Can ceftriaxone be mixed with other IV medications?
No — ceftriaxone should not be mixed with other drugs or IV fluids in the same syringe or infusion bag. Critically: NEVER mix with calcium-containing solutions (Ringer's Lactate, Hartmann's solution, total parenteral nutrition containing calcium) — this forms an insoluble precipitate that can block blood vessels. Use a separate IV line, flushed with saline, before and after ceftriaxone administration. When giving with aminoglycosides (e.g., amikacin, gentamicin), administer as separate IV infusions via separate lines.

⚕ Medical Disclaimer: Aciphin® is a prescription antibiotic for parenteral (IV) administration only by trained healthcare professionals. Product information sourced from ACI Pharmaceuticals Ltd. official prescribing data. For educational purposes only. Always follow physician's prescription and hospital antibiotic stewardship guidelines.